Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Other Routine +

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MediciNova Clears Trial Hurdle for MN-001; Q3 Data Release Looms Amidst ALS Pipeline Progress

By The Northwire Desk — AI Analysis May 26, 2026 · 19:00 4875 NaN
Executive Summary
  • The most recent release (May 26, 2026) confirms completion of Last Patient Last Visit (LPLV) for the Phase 2 trial MN-001-NATG-202 evaluating tipelukast (MN-001).
  • Top-line data for this trial is expected in Q3 2026.
  • Historical progression shows consistent execution: Enrollment completed Nov 2025, mechanistic validation published Oct/Dec 2025, and LPLV achieved May 2026.
  • Parallel pipeline updates include MN-166 (ibudilast) trials for ALS (COMBAT-ALS), Chemotherapy-induced Peripheral Neuropathy (OXTOX), and Brain Metastasis research published April 2026.
  • The company maintains regulatory designations including Orphan Drug and Fast Track status for ALS indications.
Material Impact
  • Execution Milestone: Completion of LPLV is a procedural milestone that confirms the study has finished data collection as planned, reducing execution risk regarding trial delays.
  • Timeline Confirmation: The Q3 2026 data release date aligns with previous guidance (Summer 2026) provided in November and December 2025 releases; no significant deviation or acceleration is noted.
  • Pipeline Diversification: While MN-001 progresses, the April 2026 publication regarding MN-166 for brain metastasis adds a new potential indication but remains preclinical/early translational compared to the late-stage ALS program.
  • Market Expectation: As this trial completion was anticipated following the November 2025 enrollment announcement, the news is priced in and lacks immediate surprise factor required for "Material" classification.
  • Risk Profile: The company remains dependent on binary clinical outcomes; no data has been released yet to validate efficacy or safety.
4875 · Price
Company Overview
  • Company: MediciNova is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for inflammatory, fibrotic, and metabolic diseases.
  • Flagship Project 1 (MN-166/Ibudilast): A PDE inhibitor with anti-inflammatory properties currently in Phase 2b/3 trials for ALS (COMBAT-ALS) and Phase 2 for CIPN. Holds Orphan Drug and Fast Track designations from the FDA.
  • Flagship Project 2 (MN-001/Tipelukast): An orally bioavailable small-molecule targeting leukotriene receptors, PDE3/4 inhibition, and 5-LO inhibition. Currently in Phase 2 for hypertriglyceridemia and NAFLD associated with Type 2 diabetes.
  • Mechanism: Multi-modal activity including anti-inflammatory, antifibrotic, and lipid-modulating effects.
Read the original news release →

More from NaN

Jun 30, 2026 · 08:00

Clinical-stage biotech advances late-stage neurology and metabolic assets with H2 2026 data catalysts on track.

Other Jun 08, 2026 · 08:00

Late-stage biotech advancing MN-166 across neurology and oncology, with patent wins reinforcing IP moats while pivotal clinical data remains pending.

M&A / Property Apr 27, 2026 · 19:00

MediciNova’s Ibudilast Gains Brain Metastasis Validation Ahead of ALS Readout

Other Jan 29, 2026 · 18:00

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients

Other Jan 06, 2026 · 09:00

2026 New Year's Greetings from the CEO

Other Dec 18, 2025 · 06:00

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

Other